Atlas Trials

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Clinical trial NCT05135975 · RECRUITING

Trial details

NCT number
NCT05135975
Sponsor
Nationwide Children's Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NeuroblastomaSarcoma
Start date
2022-07-20
Primary completion
2026-07-01
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.